ImmunoGen, Inc.

DB:IMU Stock Report

Market Cap: €7.8b

ImmunoGen Valuation

Is IMU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IMU (€28.74) is trading below our estimate of fair value (€29.5)

Significantly Below Fair Value: IMU is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMU?

Key metric: As IMU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IMU. This is calculated by dividing IMU's market cap by their current revenue.
What is IMU's PS Ratio?
PS Ratio29.1x
SalesUS$287.61m
Market CapUS$8.36b

Price to Sales Ratio vs Peers

How does IMU's PS Ratio compare to its peers?

The above table shows the PS ratio for IMU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.9x
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
13.6x33.4%€827.2m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
1SXP SCHOTT Pharma KGaA
4.2x10.7%€4.0b
IMU ImmunoGen
29.1x26.0%€8.4b

Price-To-Sales vs Peers: IMU is expensive based on its Price-To-Sales Ratio (29.1x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does IMU's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
IMU 29.1xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IMU is expensive based on its Price-To-Sales Ratio (29.1x) compared to the European Biotechs industry average (10.5x).

Price to Sales Ratio vs Fair Ratio

What is IMU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29.1x
Fair PS Ratio5x

Price-To-Sales vs Fair Ratio: IMU is expensive based on its Price-To-Sales Ratio (29.1x) compared to the estimated Fair Price-To-Sales Ratio (5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€27.07
0%
13.7%€29.03€17.64n/a10
Nov ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Oct ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Sep ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Aug ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Jul ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Jun ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
May ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Apr ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Mar ’25n/a
€27.07
0%
13.7%€29.03€17.64n/a10
Feb ’25€26.65
€26.83
+0.7%
13.1%€28.58€17.37n/a11
Jan ’25€26.76
€26.83
+0.3%
13.1%€28.58€17.37n/a11
Dec ’24€26.72
€26.57
-0.6%
13.7%€28.74€17.47n/a12
Nov ’24€14.03
€21.74
+55.0%
17.8%€25.43€12.24n/a12
Oct ’24€15.04
€21.99
+46.3%
16.3%€25.16€12.11n/a10
Sep ’24€14.80
€20.48
+38.4%
26.2%€24.80€8.27n/a10
Aug ’24€16.11
€20.21
+25.5%
26.0%€24.58€8.19n/a10
Jul ’24€17.16
€16.09
-6.2%
28.4%€21.94€7.31n/a10
Jun ’24€12.61
€13.13
+4.2%
29.8%€20.07€7.30n/a10
May ’24€4.98
€11.03
+121.4%
45.5%€20.05€2.73n/a10
Apr ’24€3.36
€11.25
+234.7%
46.1%€20.63€2.81n/a10
Mar ’24€3.62
€11.25
+211.1%
46.1%€20.63€2.81n/a10
Feb ’24€4.17
€11.12
+166.7%
44.4%€20.25€3.68€26.6510
Jan ’24€4.76
€11.19
+135.1%
45.3%€20.55€3.74€26.7610
Dec ’23€4.90
€12.20
+149.2%
47.2%€21.48€3.90€26.7210
Nov ’23€5.95
€10.84
+82.2%
44.5%€19.91€3.98€14.039

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

7D

-1.6%

1Y

-38.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

7D

-1.8%

1Y

0.2%